Stereoselective direct reductive amination of ketones with electron-deficient amines using Re2O7/NaPF6 catalyst
作者:Braja Gopal Das、Prasanta Ghorai
DOI:10.1039/c3ob40918j
日期:——
The first example of direct reductive amination (DRA) of ketones with electron-deficient amines (EDA) such as Cbz-, Boc-, EtOCO-, Fmoc-, Bz-, ArSO2-, etc. protected amines have been achieved using catalytic Re2O7/NaPF6. Excellent chemoselectivities as well as diastereoselectivity (for 2-alkyl cyclohexanones) were obtained.
Indole derivatives and their metal conjugates and uses thereof
申请人:Kulkarni Sudhir Appaji
公开号:US20080242652A1
公开(公告)日:2008-10-02
Provided are compounds which are indole derivatives, as well as pharmaceutical compositions containing the compounds. Also provided are methods of using the indole compounds for preventing or treating a disease, or a condition that predisposes to a disease, wherein the disease or condition is associated with activation of the serine/threonine kinase B (Akt) in an animal. The method comprises administering to the animal a preventive or treatment effective amount of the indole compound. Further provided is a method for increasing apoptosis of an animal cell comprising contacting the cell with the indole compound.
INDOLE DERIVATIVES AND THEIR METAL CONJUGATES AND USES THEREOF
申请人:Kulkarni Sudhir Appaji
公开号:US20110021485A1
公开(公告)日:2011-01-27
Provided are compounds which are indole derivatives, as well as pharmaceutical compositions containing the compounds. Also provided are methods of using the indole compounds for preventing or treating a disease, or a condition that predisposes to a disease, wherein the disease or condition is associated with activation of the serine/threonine kinase B (Akt) in an animal. The method comprises administering to the animal a preventive or treatment effective amount of the indole compound. Further provided is a method for increasing apoptosis of an animal cell comprising contacting the cell with the indole compound.
IAP BIR DOMAIN BINDING COMPOUNDS
申请人:Laurent Alain
公开号:US20130040892A1
公开(公告)日:2013-02-14
A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.